The RAAS inhibition in COVID-19 Trialists Collaboration

The Renin Angiotensin Aldosterone System (RAAS) has been widely researched within the COVID-19 setting since the start of the global pandemic in 2019. Several studies exist which evaluate the safety and efficacy of RAAS inhibition for the treatment of COVID-19 in varying populations, however, due to the pandemic, these studies have experienced significant barriers to completion. These limitations mean many studies may not have produced results with enough power to analyse clinically relevant outcomes in a single trial alone.

This collaboration combines the individual participant-level data (IPD) from several global trials randomising participants to RAAS inhibition versus placebo or standard of care during the pandemic to conduct a meta-analysis to estimate outcomes relating to the safety and efficacy of the use of renin angiotensin blockade for COVID-19. This meta-analysis will also allow for further subgroup analyses to be conducted to maximise global learnings on the use of these agents.